Get the Stockscreener App
28.89
3.31%
-0.99
After Hours:
28.75
-0.14
-0.48%
Urogen Pharma Ltd stock is traded at $28.89, with a volume of 348.51K.
It is down -3.31% in the last 24 hours and up +10.86% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
See More
Previous Close:
$29.88
Open:
$29.84
24h Volume:
348.51K
Relative Volume:
0.40
Market Cap:
$1.41B
Revenue:
$109.79M
Net Income/Loss:
$-153.49M
P/E Ratio:
-9.0006
EPS:
-3.2098
Net Cash Flow:
$-172.59M
1W Performance:
+0.38%
1M Performance:
+10.86%
6M Performance:
+11.67%
1Y Performance:
+608.09%
1-Day Range:
$28.80
$30.20
1-Week Range:
$27.34
$30.51
52-Week Range:
$3.605
$32.37
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
28.89 | 1.46B | 109.79M | -153.49M | -172.59M | -3.2098 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Jefferies | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
How UGN-103’s Phase 3 Data and NDA Timeline Could Reshape UroGen Pharma (URGN) Investors’ Outlook - simplywall.st
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge - AOL.com
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors - Yahoo Finance
URGN Stock Price, Quote & Chart | UROGEN PHARMA LTD (NASDAQ:URGN) - ChartMill
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Sector Update: Health Care - Moomoo
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says - marketscreener.com
Oppenheimer reiterates Outperform on UroGen Pharma stock By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data - Investing.com India
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA - GuruFocus
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data By Investing.com - Investing.com South Africa
URGN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
UroGen Pharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co. - Moomoo
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data - simplywall.st
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story - simplywall.st
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC - Sahm
UroGen’s UGN-103 shows 94.5% response durability in trial By Investing.com - Investing.com Australia
Why (URGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
UroGen Pharma (URGN) Reports Strong Results for UGN-103 in Bladd - GuruFocus
Paradigm reports 1.7M-share stake in UroGen (URGN) in 13G/A - Stock Titan
UroGen Moves Toward FDA Filing For UGN-103 - Citeline News & Insights
TD Bank subsidiary reports 2.62M UroGen shares (URGN) — 5.4% - Stock Titan
UroGen’s UGN-103 shows 94.5% response durability in trial - Investing.com UK
Bladder cancer drug posts 94.5% 6-month response, heads for 2026 FDA filing - Stock Titan
UroGen reports 64.5% event-free rate at three years for bladder cancer drug By Investing.com - Investing.com India
URGN: Caribou's allogeneic CAR T therapies show best-in-class potential with pivotal trials advancing - TradingView
UroGen Pharma (URGN) Reports Positive Long-Term Response Data fo - GuruFocus
UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years - Moomoo
UroGen reports 64.5% event-free rate at three years for bladder cancer drug - Investing.com
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial - The Manila Times
Urogen Pharma LtdReports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial - TradingView
ZUSDURI Median Duration of Response Still Not Reached with - GlobeNewswire
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45 - 富途牛牛
MSN Money - MSN
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast - Investing.com India
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast By Investing.com - Investing.com Nigeria
UroGen Pharma stock (IL0011408896): CMO sells 10K shares at $30 - AD HOC NEWS
UroGen Pharma 1Q Loss $23.6M >URGN - Moomoo
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):